Diazoxide Suspension
NDC Package 0254-1010-19

11-digit billing NDC: 00254101019 · Billing unit: ML · 30 ML per package

Package Information

Diazoxide suspension is diazoxide oral suspension is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions:Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. This formulation utilizes a suspension delivery system. Marketed by Par Health Usa, Llc, this product is identified by NDC 0254-1010 and is authorized under FDA application ANDA210799.

Identification & Billing

NDC Package Code
0254-1010-19
Package Description
1 BOTTLE, DROPPER in 1 CARTON / 30 mL in 1 BOTTLE, DROPPER
Product Code
11-Digit Billing Format
00254101019
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
30 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Diazoxide
Non-Proprietary Name
Diazoxide
Substance Name
Diazoxide
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Diazoxide oral suspension is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions:Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. Diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.Diazoxide oral suspension should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide oral suspension should be considered.

Regulatory & Marketing

Labeler Name
Par Health Usa, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA210799
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-21-2020
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0254-1010-19 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 30 ml in 1 bottle, dropper of Diazoxide, a human prescription drug labeled by Par Health Usa, Llc. This suspension is formulated for oral use and contains diazoxide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Par Health Usa, Llc on July 21, 2020. The current certification is valid through December 31, 2027.

How is this Par Health Usa, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00254101019. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0254-1010-19
11-Digit CMS (5-4-2)
00254-1010-19

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.